Skip to main content
Premium Trial:

Request an Annual Quote

JP Morgan Initiates Coverage of Oxford Nanopore Technologies With Overweight Rating

NEW YORK – JP Morgan on Wednesday initiated coverage of Oxford Nanopore Technologies, giving the company's shares an Overweight rating and a June 2023 price target of 725 pence ($9.78).

In a note to investors, analyst James Gordon wrote that Oxford Nanopore is a "differentiated player, operating in an attractive segment, with a very strong long-term top-line growth outlook."

But key risks include competition from established sequencing competitors, potential nanopore-based competition, pressure from falling DNA sequencing prices, and failure to achieve timely profitability.

The UK-based nanopore sequencing firm went public on the London Stock Exchange in September, raising £330.1 million ($445.1 million) and valuing the company at approximately £4.80 billion.

Gordon said he sees the DNA sequencing market doubling to approximately $8 billion by 2025 and expects Oxford Nanopore to "outperform the already strong growth of the DNA sequencing market." The company could achieve break-even in 2025, he added.

In Wednesday trading on the London Stock Exchange, shares of Oxford Nanopore were flat at 591.5 pence.

The Scan

Call for a Different Tack

Experts weigh the value of recent experiments testing genetically modified pig kidneys using brain-dead individuals, according to Nature News.

Wastewater Warning

The New York Times reports that wastewater surveillance in some parts of the US point to a possible surge.

Can't Get in the Program

Due to the Northern Ireland protocol dispute, the European Union is preventing UK researchers from joining the Horizon Europe research program, the Times of London reports.

Science Paper on Spatial-Controlled Genome Editing

In Science this week: approach to enable a CRISPR-Cas13a-based system to be used as a cancer therapy.